SCHEMBL4630409

SCHEMBL4630409

CCCCCCCC/C=C\CCCCCCCC(=O)OC(=O)CCC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 3/20 0.61
PTPN1 P18031 3/20 0.61
PPARG P37231 3/20 0.61
PPARD Q03181 3/20 0.61
PPARA Q07869 3/20 0.61
CYP1A2 P05177 2/20 0.61
MAPT P10636 2/20 0.61
CYP2C19 P33261 2/20 0.61
BLM P54132 2/20 0.61
HSD17B10 Q99714 2/20 0.61
FABP4 P15090 2/20 0.61
FAAH O00519 2/20 0.61
KMT2A Q03164 2/20 0.61
GMNN O75496 1/20 0.61
USP2 O75604 1/20 0.61
LMNA P02545 1/20 0.61
POLB P06746 1/20 0.61
CYP2C9 P11712 1/20 0.61
ALOX15 P16050 1/20 0.61
APEX1 P27695 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26444130 1.00 TERT (0.61) TERTPTPN1PPARGPPARDPPARA
SCHEMBL6744545 1.00 TERT (0.61) TERTPTPN1PPARGPPARDPPARA
SCHEMBL25298084 0.96 TERT (0.66) TERTPTPN1PPARGPPARDPPARA
SCHEMBL25298423 0.96 TERT (0.66) TERTPTPN1PPARGPPARDPPARA
SCHEMBL25290915 0.96 TERT (0.66) TERTPTPN1PPARGPPARDPPARA
SCHEMBL23041584 0.96 TERT (0.66) TERTPTPN1PPARGPPARDPPARA
SCHEMBL25291566 0.96 TERT (0.66) TERTPTPN1PPARGPPARDPPARA
SCHEMBL25287432 0.96 TERT (0.66) TERTPTPN1PPARGPPARDPPARA
SCHEMBL25298092 0.96 TERT (0.66) TERTPTPN1PPARGPPARDPPARA
SCHEMBL25287653 0.96 TERT (0.66) TERTPTPN1PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207410-A1 STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF NEURODERM, LTD. (IL) 2024-06-27 US disclosed
EP-4305049-A1 STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF Neuroderm Ltd (IL) 2024-01-17 EP disclosed
US-11844754-B2 Methods for treatment of Parkinson's disease NEURODERM, LTD. (IL) 2023-12-19 US disclosed
CN-114507555-B Biodegradable flame-retardant hydraulic oil composition 中国石油化工股份有限公司 2023-08-08 CN disclosed
WO-2023126945-A1 METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE NEURODERM, LTD. (IL) 2023-07-06 WO disclosed
US-20230157985-A1 METHODS FOR TREATMENT OF PARKINSON'S DISEASE NEURODERM, LTD. (IL) 2023-05-25 US disclosed
CN-114426897-B Gasoline engine lubricating oil composition and preparation method thereof 中国石油化工股份有限公司 2023-03-10 CN disclosed
CN-114426896-B Lubricating oil composition for diesel engine and preparation method thereof 中国石油化工股份有限公司 2023-03-10 CN disclosed
CN-112707819-B Ester compound and preparation method and application thereof 中国石油化工股份有限公司 2022-12-13 CN disclosed
EP-4025200-A1 LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF Neuroderm Ltd (IL) 2022-07-13 EP disclosed
CN-114507555-A Biodegradable flame-retardant hydraulic oil composition 中国石油化工股份有限公司 2022-05-17 CN disclosed
CN-114426897-A Gasoline engine lubricating oil composition and preparation method thereof 中国石油化工股份有限公司 2022-05-03 CN disclosed
CN-114426896-A Lubricating oil composition for diesel engine and preparation method thereof 中国石油化工股份有限公司 2022-05-03 CN disclosed
CN-112707819-A Ester compound and preparation method and application thereof 中国石油化工股份有限公司 2021-04-27 CN disclosed
WO-2021044420-A1 LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF NEURODERM, LTD. (IL) 2021-03-11 WO disclosed
EP-1924240-A1 PERSONAL CARE PRODUCTS INCORPORATING CELLULOSIC FATTY ACID ESTERS EASTMAN CHEMICAL COMPANY (US) 2008-05-28 EP disclosed
WO-2007033252-A1 PERSONAL CARE PRODUCTS INCORPORATING CELLULOSIC FATTY ACID ESTERS EASTMAN CHEMICAL COMPANY (US) 2007-03-22 WO disclosed
US-20070053855-A1 Personal care products incorporating cellulosic fatty acid esters EASTMAN CHEMICAL COMPANY 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11844754-B2 Methods for treatment of Parkinson's disease DDC, DDT, SLC6A3 TERT 4540/4885PTPN1 2845/4885PPARG 1183/4885
US-20240207410-A1 STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF COMT, TH, DDT TERT 3070/4885PTPN1 188/4885PPARG 2030/4885
US-20230157985-A1 METHODS FOR TREATMENT OF PARKINSON'S DISEASE DDC, DDT, COMT TERT 4517/4885PTPN1 2857/4885PPARG 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.